American Express Company (AXP - Free Report) just released its 2017 first quarter financial results, posting earnings of $1.34 per share and revenues of $7.9 billion. Currently, American Express is a Zacks Rank #3 (Hold) and is up 2.38% to $77.40 per share in trading shortly after its earnings report was released.
Beat earnings estimates. The company posted earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.28 per share.
Beat revenue estimates. The company saw revenue figures of $7.9 billion, just topping our consensus estimate of $7.7 billion.
In Q1, American Express saw a 13% decline in net income and 2% drop in revenues year-over-year. While profits and sales dropped, the credit card company acquired 2.6 million new card users globally and “card member spending grew 8%.”
“The results reflect many of the investments we’ve been making to grow the business, plus continued progress in reducing operating expenses,” said Chairman and CEO Kenneth I. Chenault. “Our underlying performance this quarter gives me added confidence in our ability to deliver our 2017 EPS outlook of $5.60 -$5.80 and position American Express for sustainable growth in the years ahead.”
Here’s a graph that looks at American Express:
American Express Company is primarily engaged in the business of providing travel related services, financial advisory services, and international banking services throughout the world. American Express Travel Related Services Company, Inc. provides a variety of products and services, including, global network services, the American Express Card, the Optima Card and other consumer and corporate lending products, stored value products, and several others.
Check back later for our full analysis on American Express’ earnings report!
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>